Supplementary Figure 2 from A Phase I Clinical Trial Adding OX40 Agonism to <i>In Situ</i> Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies

• DOI: 10.1158/1078-0432.28523434
• Publication Date: 2025-03-03T08:57:47Z
• Authors: Tanaya Shree; Debra Czerwinski; Sarah Haebe; Anuja Sathe; Sue Grimes; Brock Martin; Michael Ozawa; Richard Hoppe; Hanlee Ji; Ronald Levy

<p>Supplementary Figure 2. Assay for measuring OX40 saturation; Abundance and OX40 expression of T cell subsets.</p>